FDA Misses Deadline on Savara’s Inhaled Drug for Rare Lung Disease
The FDA will not meet the Nov. 22, 2026 deadline for Savara’s molgramostim BLA for autoimmune PAP. The review is ongoing with no new date set.
The FDA will not meet the Nov. 22, 2026 deadline for Savara’s molgramostim BLA for autoimmune PAP. The review is ongoing with no new date set.
JPMorgan started Savara at Overweight and $12, pointing to a Nov. 22 FDA decision, later U.K. and EU reviews, and blockbuster potential.
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
Savara’s MOLBREEVI just got FDA Priority Review for autoimmune PAP. Possible U.S. approval in August 2026 and first-ever approved therapy in US & Europe.